Accordingly, we show that resistant cells remain sensitive, albeit weakly, to BPTES, but more importantly that BPTES enhances the anti‐tumor activity of BRAF inhibition, presumably by suppressing switching to glutamine metabolism. This evidence concerns the gene BRAF and neoplasm.